The usability of novel serum glycobiomarker for the prognosis of acute liver failure

Research Project

Project/Area Number	16K19935
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Digestive surgery
Research Institution	Kyushu University
Principal Investigator	YOSHIYA Shohei 九州大学, 医学研究院, 共同研究員 (20717079)
Project Period (FY)	2016-04-01 – 2018-03-31
Project Status	Completed (Fiscal Year 2017)
Budget Amount *help	¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000) Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000) Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Keywords	肝再生 / 糖鎖 / 急性肝不全 / 予後予測 / 血清糖鎖 / バイオマーカー
Outline of Final Research Achievements	WFA+-tenascin was identified as a liver regenerating serum glycobiomarker using mouse liver regeneration model. We investigated the correlation between liver regeneration rate with 3D-CT volumetry or preserved blood specimens of living donor surgery and WFA+-tenascin, and which revealed that it is a useful liver regeneration marker in humans. In the study of liver diseases, fulminant hepatitis was high in WFA+-tenascin, and a significant positive correlation with previous prognostic prediction was found. The WFA+-tenascin value was significantly higher in the deceased group of acute liver failure cases, and the cut-off value was determined to be 5700. The usefulness as a prognostic prediction formula was examined, the specificity was 88%, sensitivity was 53%, and it was shown to be useful as prognostic prediction of acute liver failure.